https://european-biotechnology.net/wp-content/uploads/2024/09/Fenebrutinib-wikimedia.org_-e1725436453119.png450800Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-04 07:54:452024-09-04 07:54:45Roche with good interim clinical results
https://european-biotechnology.net/wp-content/uploads/2024/09/Individor-e1725432031394-1030x580-1.jpg5801030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-09-04 06:41:252024-09-04 06:41:25Individor set to waive AEF0117 licence after Phase IIb failure
https://european-biotechnology.net/wp-content/uploads/2024/08/Biopole-SA-1030x373-1.jpg3731030Thomas Gabrielczyk/wp-content/uploads/2019/12/ebn-1-300x135.pngThomas Gabrielczyk2024-08-21 06:58:372024-08-21 06:58:37Vandria closes Series A round at CHF28.3m
